Canadian woman dies after falling ill at Belgium's Tomorrowland music festival
Debby Wilmsen said in an emailed statement that a 35-year-old Canadian woman fell ill at the festival on Friday.
She said the woman was given first aid and then taken to Antwerp University Hospital, but festival organizers were told Saturday morning that the woman had died.
Wilmsen said the Antwerp public prosecutor's office is investigating the cause of death. The office did not respond to requests for information on the woman.
Global Affairs Canada said it is aware of reports that a Canadian woman has died in Belgium but said it would not release information due to privacy considerations.
Spokesperson Sabrina Williams said Global Affairs Canada is in contact with local authorities.
A massive fire engulfed the main stage two days before the annual music festival began on Friday in the town of Boom, north of Brussels.
Tomorrowland draws tens of thousands of visitors from around Europe and runs across two weekends, ending on July 27.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Sun
an hour ago
- Toronto Sun
Global Affairs Canada employee faces sexual assault charges
Gilal Eldien Ali is accused of sexually assaulting an Afghan woman who once worked for Canada in Afghanistan. A Global Affairs Canada employee is on trial at the Ottawa courthouse for sexual assault and other charges.. Photo by PATRICK DOYLE / THE CANADIAN PRESS The trial of a federal public servant who is accused of sexually assaulting a female Afghan who formerly worked for Canada in Afghanistan is under way. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Gilal Eldien Ali faces several charges that stem from allegations dating back to a period between 2011 and 2013 after the woman immigrated to Canada through a government program. The woman, whose identity is protected by a publication band, lived at the defendant's home at the time that most of the alleged abuse took place. Ali and the complainant met in Afghanistan when he was a civilian technical advisor working for Canadian International Development Agency in Kandahar from 2009 to 2012. Ali is now on leave from his job with Global Affairs Canada, according to CBC. The woman recounted the alleged abuse she suffered in court last week. 'He called me his sex toy, a whore and a bitch,' the Afghan woman said, according to CBC. This advertisement has not loaded yet, but your article continues below. Ali, who is an Ottawa resident, was back in court on July 22, when Claude Désilets, a witness, testified that Ali seemed to have a parental relationship with the woman, and that she called him 'daddy Gilal' in Afghanistan. Under cross-examination, Désilets, who worked with Ali in Afghanistan, said he had heard that things were 'not going well' a few months after she had immigrated to Canada, but added that nothing pointed to her being sexually assaulted. The court heard last week that it wasn't long after the woman moved to Canada that the alleged abuse began, according to CBC. Ali is also being sued by the woman in civil court. In that lawsuit, she is seeking $1.75 million from Ali for punitive damages, mental suffering and loss of future or past economic gain, according to CBC. The Afghan woman also sued the federal government for $1 million in damages. That lawsuit was settled out of court this summer, CBC reported. The charges Ali faces include sexual assault, sexual exploitation of a young person, assault, uttering threats and extortion. The trial will resume on Sept. 16. Read More Golf Canada Toronto & GTA Ontario World
Ottawa Citizen
2 hours ago
- Ottawa Citizen
Global Affairs Canada employee faces sexual assault charges
The trial of a federal public servant who is accused of sexually assaulting a female Afghan who formerly worked for Canada in Afghanistan is under way. Article content Gilal Eldien Ali faces several charges that stem from allegations dating back to a period between 2011 and 2013 after the woman immigrated to Canada through a government program. The woman, whose identity is protected by a publication band, lived at the defendant's home at the time that most of the alleged abuse took place. Article content Article content Article content Ali and the complainant met in Afghanistan when he was a civilian technical advisor working for Canadian International Development Agency in Kandahar from 2009 to 2012. Ali is now on leave from his job with Global Affairs Canada, according to CBC. Article content Article content The woman recounted the alleged abuse she suffered in court last week. Article content 'He called me his sex toy, a whore and a bitch,' the Afghan woman said, according to CBC. Article content Ali, who is an Ottawa resident, was back in court on July 22, when a witness testified that Ali seemed to have a parental relationship with the woman, and that she called him 'daddy Gilal' in Afghanistan. Article content Under cross-examination, the witness, who worked with Ali in Afghanistan, said he had heard that things were 'not going well' a few months after she had immigrated to Canada, but added that nothing pointed to her being sexually assaulted. Article content Article content The court heard last week that it wasn't long after the woman moved to Canada that the alleged abuse began, according to CBC. Article content Article content Ali is also being sued by the woman. Article content In that lawsuit, she is seeking $1.75 million from Ali for punitive damages, mental suffering and loss of future or past economic gain, according to CBC. Article content The Afghan woman also sued the federal government for $1 million in damages. That lawsuit was settled out of court this summer, CBC reported. Article content Article content Article content
Globe and Mail
2 hours ago
- Globe and Mail
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest portfolios in the sector, with a strong presence in oncology, cardiovascular disease, inflammation, bone health and rare disease markets. On the other hand, Novo Nordisk enjoys a leading position in the diabetes and obesity market, while steadily expanding its presence into rare diseases. Both these giants have established strong footholds in their respective target markets, delivering consistent returns to shareholders. In such a scenario, choosing one stock over another can be challenging. Let's examine the fundamentals of the two stocks to make a prudent choice. The Case for AMGN Amgen's diverse portfolio and global reach position it well in a changing pharma landscape. Growth products like Repatha, Prolia, Xgeva, Evenity, Vectibix, Nplate, Kyprolis and Blincyto are performing well, having gained approvals for label expansions. The robust sales of these drugs have helped Amgen offset the declining sales of its legacy drugs such as Enbrel. The 2023 acquisition of Horizon Therapeutics has significantly expanded Amgen's rare disease business by adding several rare disease drugs, including Tepezza, Krystexxa and Uplizna, to its portfolio. Amgen is one of the handful of companies that is evaluating an obesity drug in late-stage development. In March, the company started two phase III studies evaluating its investigational GIPR/GLP-1 receptor MariTide for 72 weeks in people with obesity, with or without type II diabetes (T2D). Additional late-stage studies on the drug in specific obesity-related conditions are expected to start throughout 2025. Unlike the currently marketed obesity drugs like Novo's Wegovy and Eli Lilly 's LLY Zepbound that require weekly injections, MariTide is being tested for monthly dosing. The late-stage development of the drug was supported by data from phase II studies, wherein treatment with MariTide resulted in up to approximately 20% average weight loss over 52 weeks, without reaching a weight loss plateau in people who were obese or overweight but without T2D. However, the weight loss reduction was at the lower end of investor expectations of 20-25%. In T2D patients who were obese or overweight, the weight loss reduction was approximately 17% at 52 weeks. Beyond obesity, Amgen has promising late-stage pipeline drugs across several therapeutic areas, which represent significant commercial potential. These include bemarituzumab (for first-line gastric cancer), rocatinlimab (for eczema and prurigo nodularis) and olpasiran (for atherosclerotic cardiovascular disease). Amgen has also strengthened its biosimilar portfolio, with the recent launches of biosimilar versions of popular drugs like J&J's Stelara (marketed as 'Wezlana') and Regeneron's Eylea ('Pavblu'). It is also developing biosimilar versions of blockbuster oncology drugs like Bristol Myers' Opdivo and Merck's Keytruda in ongoing phase III studies. However, increased pricing headwinds and competitive pressure are negatively impacting the sales of many products. Sales of best-selling drugs, Prolia and Xgeva, are expected to decline in 2025, mainly from the second half, due to patent erosion. The Case for NVO Novo Nordisk has achieved tremendous success in the GLP-1 space, all thanks to its semaglutide drugs sold under the brand names Ozempic (for T2D) and Wegovy (for obesity). As of March 2025-end, Novo continues to be the global market leader in the GLP-1 segment, with around 54% value market share. Sales of Wegovy continue to rise due to strong prescription growth, driving higher revenues and profits. Additionally, Ozempic sales are also contributing positively to overall revenues. NVO has been investing heavily to expand its manufacturing capacity as part of its strategic move to entrench its diabetes and obesity care market leadership for its GLP-1 products. Novo Nordisk is pursuing new indications for semaglutide, including label expansions for Wegovy in additional cardiovascular conditions and for Ozempic in T2D patients with chronic kidney disease. It is also investigating semaglutide's potential in metabolic dysfunction–associated steatohepatitis (MASH). These efforts could expand the eligible patient population for semaglutide and boost sales. However, the company's arch-rival Eli Lilly remains a formidable adversary in the obesity market, which threatens its market share. Lilly markets its tirzepatide injections under the brand names Mounjaro for T2D and Zepbound for obesity. The NVO stock has also been under pressure due to disappointing data from two late-stage studies for its next-generation subcutaneous obesity candidate, CagriSema, a follow-up drug to Wegovy. In these studies, CagriSema demonstrated a lower-than-expected reduction in body weight. Novo Nordisk is also currently facing a major transition in its executive management, as CEO Lars Fruergaard Jørgensen will step down due to market headwinds and a decline in the company's stock since mid-2024. The search for his successor is currently underway. Though the rare disease segment currently accounts for a minimal portion of revenues, Novo is making good efforts to expand this portfolio. A regulatory filing with the FDA, seeking approval for Mim8 in patients aged 12 years and older with hemophilia A, is planned for submission later this year. How Do Estimates Compare for AMGN & NVO? The Zacks Consensus Estimate for Amgen's 2025 sales implies a year-over-year increase of 5%, and that for EPS also suggests an improvement of 5%. EPS estimates for 2025 and 2026 have moved north in the past 60 days. The Zacks Consensus Estimate for Novo's 2025 sales and EPS implies a year-over-year increase of around 20% and 21%, respectively. While EPS estimates for 2025 have been trending upward over the past 60 days, the same for 2026 have moved south. Price Performance and Valuation of AMGN & NVO Year to date, shares of Amgen have gained 17%, while those of Novo have plummeted 22%. In comparison, the industry has declined 3%, as seen in the chart below. From a valuation standpoint, Novo Nordisk seems to be slightly more expensive than Amgen, going by the price/book (P/E) ratio. NVO's shares currently trade at 15.51 times forward earnings, higher than 14.5 for AMGN. In terms of dividend yield, Amgen stands higher at 3.1% compared to Novo's 2.5%. AMGN or NVO: Which Is a Better Pick? Both Amgen and Novo carry a Zacks Rank #3 (Hold) each, which makes choosing one stock over the other difficult. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. However, when comparing the two, Amgen appears to be the better pick. Despite short-term headwinds like Prolia and Xgeva going off patent later this year, the company's diversified portfolio and deep pipeline offer a balanced growth story. AMGN stock also looks more attractive than NVO from a valuation standpoint. While Novo Nordisk continues to lead in the GLP-1 space with strong revenue growth, it faces several near-term challenges. These include limited diversification, underwhelming CagriSema results and a leadership transition — all of which may weigh on investor sentiment. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report
